RLMD Relmada Therapeutics, Inc.
$2.86
Relmada Therapeutics, Inc. (RLMD) Earnings News
Earnings press releases, previews and reviews for Relmada Therapeutics, Inc. (RLMD), newest first. Our most recent is review: Relmada Beats on Per-Share Loss, but Dilution Drives the Number as 18-Month NDV-01 Data Reveal Its First Progressions.
Thursday
November 12, 2026
6:53 PM ET
Relmada Beats on Per-Share Loss, but Dilution Drives the Number as 18-Month NDV-01 Data Reveal Its First Progressions
Earnings Whispers · Review
Thursday
November 12, 2026
4:05 PM ET
Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Wednesday
November 4, 2026
6:24 PM ET
Relmada's Q3 Report Is a Test of Whether NDV-01's Year-End IND Timeline Holds
Earnings Whispers · Preview
Tuesday
November 3, 2026
7:00 AM ET
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
Thursday
August 6, 2026
4:05 PM ET
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Thursday
July 16, 2026
7:05 AM ET
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026